$JNCE Jounce Therapeutics, Inc. (NASDAQ:JNCE): Transforming Cancer Treatment Through Innovative Immunotherapies https://beyondspx.com/article/jounce-therapeutics-inc-nasdaq-jnce-transforming-cancer-treatment-through-innovative-immunotherapies
$MRKR have loved this one through thick and thin. Miss teaming them with their buddy $JNCE (since bought out). That's how old school I am on this one. Time to accumulate before movement. This will creep up over time. Solid buy and hold as we eye the finish line.
Follow/Subscribe for more suggestions and perspective. Would love to hear yours too...that's how we find hidden gems and make money.
Let's make some money! Cheers!
$JNCE Jounce Therapeutics, Inc. (NASDAQ:JNCE): Transforming Cancer Treatment Through Innovative Immunotherapies http://beyondspx.com/2024/08/05/jounce-therapeutics-inc-nasdaqjnce-transforming-cancer-treatment-through-innovative-immunotherapies/
@TB_Goat my complete bad on this one. That might be why it's been red all of this time. For those that don't know, $JNCE was acquired by Concentra last year (although still showing up on stocktwits as stand alone stock) TB, great catch!
$PIRS is there any life with this one anymore? Sold for profit a few years back for around 3$ which is looking pretty good right now. Should have done the same with $JNCE and $MRKR although I think they still have legs as their trial results come in. The Jim Allison science is incredible
$NBSE algos are your good friend to get this stock at cheap price. They bring down price for all stocks when there is lack of volume, they don't see if there is SA in progress or how much cash business has. $jnce was brought down below $1 and was finally closed at over $1.8 with offer from Tang capital. $frtx was brought below .6 and company decided to distribute cash with range of 0.9 to 1.1+ so stock just shoot to 50% + when news got published. Here also it looks very safe to me given cash burn is very minimal in last quarter. So only small risk is if management turns rough and give away cash to company it merges with cheap. But that would be very difficult to defend and they will be sued, so I think outcome will be like jnce or frtx. Remember they said in September giving $1 dividend is not in best interest of shareholders and they are working to benefit most to SH
As always Tang and Concentra like to play cheap eh. The point is that if $RAIN board is smart they will rise the price more than $JNCE and won't make the same mistake of $AVIR that has now lost 50%.. The biotech market is dead, interest rates are skyhigh, inflations is huge and there are two big wars going on in the world so refuse would be a move that only id10ts like Avir would make.
